FloLipid is a liquid cholesterol medicine taken as an oral suspension rather than a tablet. Now the U.S. Food and Drug Administration (FDA) has proposed withdrawing its approval. The notice does not cite contamination or a safety problem. Its stated basis is missing annual paperwork from the company that holds the approval, and that company has a deadline to respond.
The FloLipid FDA withdrawal 2026 notice was published in the Federal Register on November 18, 2026, at 91 FR 74176. It is filed under Docket No. FDA-2026-N-9703. The notice covers new drug application (NDA) 206679 for FloLipid, a liquid form of the cholesterol-lowering statin simvastatin, approved in 20 mg/5 mL and 40 mg/5 mL strengths. The holder is Salerno Pharmaceuticals of Tulsa, Oklahoma. The proposal was signed by Michael Davis, Director of the Center for Drug Evaluation and Research (CDER). Salerno has until December 18, 2026 to request a hearing. It has until January 19, 2027 to submit the data and analyses that its hearing request relies on, and public comments close the same day.
For patients, the next step is the key date. If Salerno does not request a hearing by December 18, 2026, the notice says the FDA will then withdraw approval. Once approval is withdrawn, FloLipid may not thereafter be lawfully introduced or delivered for introduction into interstate commerce. Patients who use FloLipid should discuss any change in their treatment with their prescriber or pharmacist. The notice sets no date for any supply change, and as of November 19, 2026, no final withdrawal order has been issued. Do not stop taking your medicine without talking to your prescriber first.
Paperwork Noncompliance vs. Product Recall
Under FDA rules at 21 CFR 7.3(g), a recall is a firm’s removal or correction of a marketed product that FDA considers to be in violation of the laws it administers. This notice is a different kind of action. The FDA’s stated basis is that Salerno has repeatedly failed to file required annual reports for NDA 206679. Annual reports are yearly filings that drug makers must send the FDA under federal rules at 21 CFR 314.81. According to the notice, the holder has not responded to the agency’s requests for them. The proposal is made under section 505(e) of the Federal Food, Drug, and Cosmetic Act. For comparison, Karmactive has reported on an FDA acetaminophen recall for tablets sold on Amazon, which was a product-quality case.
What makes this case unusual is the gap between the cause and the consequences. The stated problem is a filing failure, not a product-safety finding, and the notice does not discuss how patients would be affected. Under the notice, a hearing request must include data showing a genuine and substantial issue of fact. The immediate next procedural step depends on whether Salerno timely requests a hearing, and any final outcome remains subject to FDA’s administrative process.
Why is the FDA proposing to withdraw approval of FloLipid?
The FDA’s Center for Drug Evaluation and Research proposed the withdrawal in a November 18, 2026 Federal Register notice. The stated reason is that Salerno Pharmaceuticals, which holds the approval for NDA 206679, has repeatedly failed to file required annual reports. The notice does not describe a contamination or safety recall.
Is FloLipid being recalled for safety or contamination?
No. A recall is the removal or correction of a marketed product that FDA considers to be in violation of the laws it administers. This action is a proposed withdrawal of approval, based on missing annual reports. The notice does not state a safety or contamination finding as its basis.
What are the deadlines for Salerno Pharmaceuticals to respond to the FDA?
Salerno may request a hearing by December 18, 2026. It has until January 19, 2027 to submit the data and analyses its request relies on. Public comments on the proposal also close January 19, 2027. If no hearing request arrives by December 18, the notice says the FDA will withdraw approval.
The FDA has proposed withdrawing approval for FloLipid because its holder has not filed required annual reports, not because of a safety problem. Salerno has until December 18, 2026 to request a hearing. This is a U.S. federal action, so UK and Australian readers should check with their own regulator and pharmacist about availability. Written hearing requests must cite Docket No. FDA-2026-N-9703. For other FDA drug decisions, see Karmactive’s report on the approval of Gazyva (obinutuzumab) for primary membranous nephropathy.